Join
Live feed
·
PRReleasevia Quantisnow
Rallybio Corporation logo

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

ByQuantisnow·Wall Street's wire, on your screen.
RLYB· Rallybio Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLYB (Rallybio Corporation) and more on Quantisnow.